Drug Repositioning Discovery for Early- and Late-Stage Non-Small-Cell Lung Cancer

Table 7

Summary of top pathways returned by KEGG using CPDB for early- and late-stage cancer.

Early-stage NSCLC
Term	Effective size	% of overlap	value
Leukocyte transendothelial migration	118	3.4%
Glycolysis/gluconeogenesis	66	4.5%	0.000250
Epithelial cell signaling in Helicobacter pylori infection	68	4.4%	0.000273
HIF-1 signaling pathway	106	2.8%	0.00100
Tight junction	134	2.2%	0.00197
Cell adhesion molecules (CAMs)	147	2.0%	0.00257
Late-stage NSCLC
Term	Effective size	% of overlap	value
Cell cycle	124	9.7%
Oocyte meiosis	110	7.3%
Progesterone-mediated oocyte maturation	86	7.0%
DNA replication	36	8.3%	0.00100
Epstein-Barr virus infection	203	2.5%	0.00512
Viral carcinogenesis	206	2.4%	0.00544
p53 signaling pathway	68	4.4%	0.00620
Measles	134	3.0%	0.00630
Hepatitis B	146	2.7%	0.00849